Cargando…
Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations
Checkpoint inhibitors (CPIs) are monoclonal antibodies which, by disrupting interactions of immune checkpoint molecules with their ligands, block regulatory immune signals otherwise exploited by cancers. Despite revolutionary clinical benefits, CPI use is associated with an array of immune-related a...
Autores principales: | Williams, Kristian C., Gault, Abigail, Anderson, Amy E., Stewart, Christopher J., Lamb, Christopher A., Speight, R. Ally, Rajan, Neil, Plummer, Ruth, Pratt, Arthur G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909476/ https://www.ncbi.nlm.nih.gov/pubmed/36776862 http://dx.doi.org/10.3389/fimmu.2023.1122430 |
Ejemplares similares
-
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
por: Naidoo, Jarushka, et al.
Publicado: (2017) -
Treatment-related adverse events as surrogate to response rate to immune checkpoint blockade
por: Shen, Yanyun, et al.
Publicado: (2020) -
High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer
por: Kuo, Alyce M., et al.
Publicado: (2022) -
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade
por: Hu, Weilei, et al.
Publicado: (2020) -
Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
por: Abdel-Wahab, Noha, et al.
Publicado: (2016)